ScreenerHero

CTMX CytomX Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · cytomx.com
2.550USD-0.39%Mkt Cap: 555.64M $P/E: —

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platfo…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap555.64M USD
Enterprise Value233.25M USD
Revenue (TTM)18.30M USD
Gross Profit18.30M USD
Net Income (TTM)-17.37M USD
Revenue/Share0.10 USD
Last Price2.550 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees69
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.41
PEG—
EV/EBITDA-2.71
EV/Revenue12.74
P/S30.48
P/B1.85
EPS (TTM)-0.51
EPS (Forward)-0.47
52W Range
2.3304% of range8.210
52W High8.210 USD
52W Low2.330 USD
Profitability
Gross Margin100.00%
Oper. Margin-1677.08%
EBITDA Margin0.00%
Profit Margin-22.79%
ROE-17.54%
ROA-11.46%
Growth
Revenue Growth-92.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-75.59M USD
CapEx (TTM)220.00K USD
FCF Margin-410.93%
FCF Yield-13.54%
Net Debt-324.58M USD
Net Debt/EBITDA3.76
Balance Sheet
Debt/Equity0.04
Current Ratio9.36
Quick Ratio9.26
Book Value/Sh1.39 USD
Cash/Share1.52 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)12.25 USD
Upside (mean)+380.4%
Target Range6.000 USD – 16.00 USD
6.000+380.4% to mean16.00
# Analysts8
Ownership
Shares Out.217.90M
Float179.66M
Insiders0.57%
Institutions104.11%
Short Interest
Short Ratio11.0d
Short % Float20.12%
Short % Out.17.73%
Shares Short38.64M
Short (prev mo.)34.62M
Technical
SMA 503.189 (-20.0%)
SMA 2004.046 (-37.0%)
Beta2.20
S&P 52W Chg16.45%
Avg Vol (30d)3.71M
Avg Vol (10d)3.64M
Technical Indicators
RSI (14)31.6
MACD-0.2079
MACD Signal-0.1896
MACD Hist.-0.0183
BB Upper3.552 USD
BB Middle2.873 USD
BB Lower2.193 USD
BB Width47.29%
ATR (14)0.1706 USD
Vol Ratio (20d)0.63x